Carryover effect on next-day sleepiness and psychomotor performance of nighttime administered antihistaminic drugs: A randomized controlled trial

Human Psychopharmacology

Volumn 27, Issue 4, 2012, Pages 428-436

  Katayose, Yasuko ^a   Aritake, Sayaka ^b   Kitamura, Shingo ^a   Enomoto, Minori ^a   Hida, Akiko ^a   Takahashi, Kiyohisa ^c   Mishima, Kazuo ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c The Japan Foundation   (Japan)

Author keywords

antihistaminic drugs; carryover effect; diphenhydramine; ketotifen; zolpidem

Indexed keywords

ANTIHISTAMINIC AGENT; DIPHENHYDRAMINE; KETOTIFEN; PLACEBO; ZOLPIDEM;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAYTIME SOMNOLENCE; DOUBLE BLIND PROCEDURE; DRUG PENETRATION; EVENING DOSAGE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

BLOOD-BRAIN BARRIER; CROSS-OVER STUDIES; DIPHENHYDRAMINE; DOUBLE-BLIND METHOD; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPNOTICS AND SEDATIVES; KETOTIFEN; MALE; POLYSOMNOGRAPHY; PSYCHOMOTOR PERFORMANCE; PYRIDINES; SLEEP; SLEEP STAGES; TIME FACTORS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84864141894     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2244     Document Type: Article

References (32)

1. AASM. 2005. International Classification of Sleep Disorders: Diagnostic and Coding Manual, 2nd edn. American Academy of Sleep Medicine: Westchester.
2. Adam K, Oswald I,. 1986. The hypnotic effects of an antihistamine: promethazine. Br J Clin Pharmacol 22: 715-717.
3. Alloway CE, Ogilvie RD, Shapiro CM,. 1997. The alpha attenuation test: assessing excessive daytime sleepiness in narcolepsy-cataplexy. Sleep 20: 258-266.
4. Asnis GM, Chakraburtty A, DuBoff EA, et al,. 1999. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 60: 668-676.
5. Benavides J, Peny B, Durand A, Arbilla S, Scatton B,. 1992. Comparative in vivo and in vitro regional selectivity of central omega (benzodiazepine) site ligands in inhibiting [3H]flumazenil binding in the rat central nervous system. J Pharmacol Exp Ther 263: 884-896.
6. Boyle J, Eriksson M, Stanley N, Fujita T, Kumagi Y,. 2006. Allergy medication in Japanese volunteers: treatment effect of single doses on nocturnal sleep architecture and next day residual effects. Curr Med Res Opin 22: 1343-1351.
7. Buysse D,. 2011. Clinical pharmacology of other drugs used as hypnotics. In Principles and Practice of Sleep Medicine. W. B. Saunders Company: Philadelphia.
8. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S,. 1986. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 9: 519-524.
9. Church MK, Maurer M, Simons FE, et al,. 2010. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 65: 459-466.
10. Depoortere H, Zivkovic B, Lloyd KG, et al,. 1986. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237: 649-658.
11. Fava M, McCall WV, Krystal A, et al,. 2006. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59: 1052-1060.
12. Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI,. 1974. Metabolic disposition of diphenhydramine. Clin Pharmacol Ther 16: 1066-1076.
13. Kirchner WK,. 1958. Age differences in short-term retention of rapidly changing information. J Exp Psychol 55: 352-358.
14. McCormack HM, Horne DJ, Sheather S,. 1988. Clinical applications of visual analogue scales: a critical review. Psychol Med 18: 1007-1019.
15. Newman JP, Widom CS, Nathan S,. 1985. Passive avoidance in syndromes of disinhibition: psychopathy and extraversion. J Pers Soc Psychol 48: 1316-1327.
16. Novartis P,. 2002. Drug Interview Form Zadeiten®
17. Perrault G, Morel E, Sanger DJ, Zivkovic B,. 1990. Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics. Eur J Pharmacol 187: 487-494.
18. Rechtschaffen A, Kales A,. 1968. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. US Government Printing Office: Washington DC.
19. Rojas-Zamorano JA, Esqueda-Leon E, Jimenez-Anguiano A, Cintra-McGlone L, Mendoza Melendez MA, Velazquez Moctezuma J,. 2009. The H1 histamine receptor blocker, chlorpheniramine, completely prevents the increase in REM sleep induced by immobilization stress in rats. Pharmacol Biochem Behav 91: 291-294.
20. Sanger DJ, Benavides J, Perrault G, et al,. 1994. Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 18: 355-372.
21. Sherwood N, Kerr J,. 1993. The reliability, validity and pharmacosensitivity of four psychomotor tests. In Human Psychopharmacology, Vol. 4. John Wiley & Sons: Hoboken.
22. Simons FE,. 1994. The therapeutic index of newer H1-receptor antagonists. Clin Exp Allergy 24: 707-723.
23. Stewart R, Besset A, Bebbington P, et al,. 2006. Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep 29: 1391-1397.
24. Tashiro M, Horikawa E, Mochizuki H, et al,. 2005. Effects of fexofenadine and hydroxyzine on brake reaction time during car-driving with cellular phone use. Hum Psychopharmacol 20: 501-509.
25. Tashiro M, Mochizuki H, Sakurada Y, et al,. 2006. Brain histamine H1 receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol 61: 16-26.
26. Tashiro M, Duan X, Kato M, et al,. 2008. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin. Br J Clin Pharmacol 65: 811-821.
27. Tiplady B,. 1988. A continuous attention test for the assessment of the acute behavioral effects of drugs. Psychopharmacol Bull 24: 213-216.
28. Tsujii T, Masuda S, Yamamoto E, et al,. 2009. Effects of sedative and nonsedative antihistamines on prefrontal activity during verbal fluency task in young children: a near-infrared spectroscopy (NIRS) study. Psychopharmacology (Berl) 207: 127-132.
29. Wechsler D,. 1955. Manual for the Wechsler Adult Intelligence Scale. The Psychological Corporation: New York.
30. Weiler JM, Bloomfield JR, Woodworth GG, et al,. 2000. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 132: 354-363.
31. Yanai K, Tashiro M,. 2007. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 113: 1-15.
32. Zhang D, Tashiro M, Shibuya K, et al,. 2010. Next-day residual sedative effect after nighttime administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured by positron emission tomography. J Clin Psychopharmacol 30: 694-701.